|
Summarize the evidence for emerging biologic and small molecule therapies in IBD, including TL1A antagonists, IL-23 inhibitors, and anti-fibrotic agents, and identify appropriate patient populations for each.
|
|
|
|
Review current surgical and endoscopic management approaches to ulcerative colitis, integrating multidisciplinary perspectives.
|
|
|
|
Evaluate the evidence for and against dual biologic therapy in IBD, including patient selection criteria, safety considerations, and monitoring strategies.
|
|
|
|
Discuss evolving treatment targets and the implications of a treat-to-target strategy for long-term disease management in IBD.
|
|
|